Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2570)	1/16/2001 8:23:53 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 52153

PIII therapeutic vaccine - From VICL web site. <<Based on this promising data, and following discussions with the FDA, we began registration trials in May 1998. These trials are ongoing in multiple centers across the United States. In our Phase II trial we are actively recruiting patients with soft-tissue metastatic melanoma who have exhausted conventional therapies. For our Phase III trial we are actively recruiting patients that have metastatic melanoma and who have not received chemotherapy. The objective of this trial is to compare treatment with dacarbazine, the only chemotherapeutic agent approved by the FDA for metastatic melanoma, to treatment with a combination of dacarbazine plus Allovectin-7®. Positive results from either or both of these trials could allow us to apply to the FDA for approval to market Allovectin-7®. We announced in December 1999 that we would continue to recruit patients as planned in our two ongoing registration trials with Allovectin-7® in patients with metastatic melanoma, based on the recommendations of an independent Drug Safety Review Board.>> For addl info on the product & trial history, see their web site, www.vical.com (from a company that does not self hype, promise to be profitable in 1999, or massively dilute - just executes) Scott